CN Patent

CN103664929B — 达沙替尼多晶型药物及制备方法

Assigned to Shijiazhuang Pharmaceutical Group Ouyi Pharma Co Ltd · Expires 2016-08-03 · 10y expired

What this patent protects

本发明提供了一种新的达沙替尼多晶型药物以及制备方法。本发明的达沙替尼多晶型物Ⅲ的粉末衍射图谱中2θ在6.2±0.2、12.0±0.2、15.3±0.2和18.4±0.2处有衍射峰。本发明制备得到的晶型化学稳定性好，纯度高。制备方法工艺条件温和，操作简单，质量稳定可控，收率高，适合产业化生产。

USPTO Abstract

本发明提供了一种新的达沙替尼多晶型药物以及制备方法。本发明的达沙替尼多晶型物Ⅲ的粉末衍射图谱中2θ在6.2±0.2、12.0±0.2、15.3±0.2和18.4±0.2处有衍射峰。本发明制备得到的晶型化学稳定性好，纯度高。制备方法工艺条件温和，操作简单，质量稳定可控，收率高，适合产业化生产。

Drugs covered by this patent

Patent Metadata

Patent number
CN103664929B
Jurisdiction
CN
Classification
—
Expires
2016-08-03
Drug substance claim
No
Drug product claim
No
Assignee
Shijiazhuang Pharmaceutical Group Ouyi Pharma Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.